Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 12, 2024
Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company, has announced a business update conference call and webcast scheduled for August 12, 2024, at 8:30 AM ET. The event will feature:
- A business update and overview of operations by CEO Lishan Aklog, M.D.
- Discussion of the company's growth strategy
- Presentation of Q2 2024 financial results by CFO Dennis McGrath
Interested parties can access the webcast via the investor relations section of luciddx.com. For telephone access, U.S. callers should dial 1-800-836-8184, while international listeners should use 1-646-357-8785. The conference call name is "Lucid Diagnostics Business Update". A 30-day replay will be available on the company's website after the call.
Lucid Diagnostics (Nasdaq: LUCD), una compagnia di diagnostica medica per la prevenzione del cancro in fase commerciale, ha annunciato una chiamata di aggiornamento aziendale e una diretta web programmata per il 12 agosto 2024 alle 8:30 AM ET. L'evento comprenderà:
- Un aggiornamento aziendale e una panoramica delle operazioni a cura del CEO Lishan Aklog, M.D.
- Discussione sulla strategia di crescita dell'azienda
- Presentazione dei risultati finanziari del secondo trimestre 2024 da parte del CFO Dennis McGrath
Le parti interessate possono accedere alla diretta web tramite la sezione delle relazioni con gli investitori di luciddx.com. Per l'accesso telefonico, i chiamanti statunitensi dovrebbero comporre il 1-800-836-8184, mentre gli ascoltatori internazionali dovrebbero usare il 1-646-357-8785. Il nome della chiamata è "Aggiornamento Aziendale Lucid Diagnostics". Una registrazione di 30 giorni sarà disponibile sul sito dell'azienda dopo la chiamata.
Lucid Diagnostics (Nasdaq: LUCD), una compañía de diagnóstico médico en etapa comercial para la prevención del cáncer, ha anunciado una llamada de actualización empresarial y un webcast programado para el 12 de agosto de 2024 a las 8:30 AM ET. El evento contará con:
- Una actualización empresarial y una visión general de las operaciones por parte del CEO Lishan Aklog, M.D.
- Discusión sobre la estrategia de crecimiento de la empresa
- Presentación de los resultados financieros del segundo trimestre de 2024 por el CFO Dennis McGrath
Las partes interesadas pueden acceder al webcast a través de la sección de relaciones con inversores de luciddx.com. Para acceso telefónico, los llamadores de EE. UU. deben marcar el 1-800-836-8184, mientras que los oyentes internacionales deben utilizar el 1-646-357-8785. El nombre de la llamada es "Actualización Empresarial de Lucid Diagnostics". Una repetición de 30 días estará disponible en el sitio web de la empresa después de la llamada.
루시드 진단 (Nasdaq: LUCD), 상업 단계의 암 예방 의료 진단 회사가 2024년 8월 12일 오전 8시 30분 ET에 예정된 사업 업데이트 전화 회의 및 웹 캐스트를 발표했습니다. 이 행사에서는:
- CEO 리샨 악클로그 박사가 진행하는 사업 업데이트 및 운영 개요
- 회사의 성장 전략에 대한 논의
- CFO 데니스 맥그라스에 의한 2024년 2분기 재무 결과 발표
관심 있는 분들은 luciddx.com의 투자자 관계 섹션을 통해 웹 캐스트에 액세스할 수 있습니다. 전화 접속의 경우, 미국의 발신자는 1-800-836-8184로 전화해야 하며, 해외 청취자는 1-646-357-8785를 사용해야 합니다. 전화 회의 이름은 "루시드 진단 사업 업데이트"입니다. 통화 후 30일간 재생이 회사 웹사이트에서 제공됩니다.
Lucid Diagnostics (Nasdaq: LUCD), une entreprise de diagnostics médicaux en phase commerciale pour la prévention du cancer, a annoncé une conférence téléphonique et un webinaire de mise à jour des affaires prévu pour le 12 août 2024 à 8h30 ET. L'événement comprendra :
- Une mise à jour des affaires et un aperçu des opérations par le CEO Lishan Aklog, M.D.
- Une discussion sur la stratégie de croissance de l'entreprise
- Présentation des résultats financiers du deuxième trimestre 2024 par le CFO Dennis McGrath
Les parties intéressées peuvent accéder au webinaire via la section des relations investisseurs de luciddx.com. Pour l'accès téléphonique, les appelants américains doivent composer le 1-800-836-8184, tandis que les auditeurs internationaux doivent utiliser le 1-646-357-8785. Le nom de la conférence téléphonique est "Mise à jour des affaires de Lucid Diagnostics". Un replay de 30 jours sera disponible sur le site de l'entreprise après l'appel.
Lucid Diagnostics (Nasdaq: LUCD), ein Unternehmen für medizinische Diagnostik im Bereich der Krebsprävention in der kommerziellen Phase, hat eine Konferenzschaltung und einen Webcast zur Geschäftseröffnung angekündigt, die für den 12. August 2024 um 8:30 Uhr ET geplant ist. Die Veranstaltung beinhaltet:
- Ein Geschäftsupdate und einen Überblick über die Abläufe von CEO Lishan Aklog, M.D.
- Diskussion der Wachstumsstrategie des Unternehmens
- Präsentation der finanziellen Ergebnisse des 2. Quartals 2024 durch den CFO Dennis McGrath
Interessierte können über den Bereich für Investoren auf luciddx.com auf den Webcast zugreifen. Für den telefonischen Zugang sollten Anrufer aus den USA 1-800-836-8184 wählen, während internationale Zuhörer 1-646-357-8785 verwenden sollten. Der Name der Konferenzschaltung lautet "Lucid Diagnostics Geschäft Update". Eine 30-tägige Wiederholung wird nach der Sitzung auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
Conference Call and Webcast at 8:30AM Eastern Time
The webcast will be available at the investor relations section of the Company's website at luciddx.com. Alternatively, to access the conference call by telephone,
Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-hold-a-business-update-conference-call-and-webcast-on-august-12-2024-302207802.html
SOURCE Lucid Diagnostics
FAQ
When is Lucid Diagnostics (LUCD) holding its business update conference call?
How can investors access Lucid Diagnostics' (LUCD) Q2 2024 financial results?
What topics will be covered in Lucid Diagnostics' (LUCD) August 12 conference call?
How can investors join Lucid Diagnostics' (LUCD) August 12 conference call?
